These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 19634108)

  • 1. 20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials--analysis of 1098 patients in four centers.
    Stephan C; Bangma C; Vignati G; Bartsch G; Lein M; Jung K; Philippe M; Semjonow A; Catalona WJ
    Int J Biol Markers; 2009; 24(2):65-9. PubMed ID: 19634108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards.
    Stephan C; Kahrs AM; Klotzek S; Reiche J; Müller C; Lein M; Deger S; Miller K; Jung K
    Clin Chem Lab Med; 2008; 46(5):623-9. PubMed ID: 18839463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer screening: clinical impact of WHO calibration of Beckman Coulter Access prostate-specific antigen assays.
    Fillée C; Tombal B; Philippe M
    Clin Chem Lab Med; 2010 Feb; 48(2):285-8. PubMed ID: 20001849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem?
    Stephan C; Köpke T; Semjonow A; Lein M; Deger S; Schrader M; Miller K; Jung K
    Clin Chem Lab Med; 2009; 47(11):1325-31. PubMed ID: 19778292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standardization of PSA measures: a reappraisal and an experience with WHO calibration of Beckman Coulter Access Hybritech total and free PSA.
    Vignati G; Giovanelli L
    Int J Biol Markers; 2007; 22(4):295-301. PubMed ID: 18161661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Three Assays for Total and Free PSA Using Hybritech and WHO Calibrations.
    Garrido MM; Marta JC; Ribeiro RM; Pinheiro LC; Holdenrieder S; Guimarães JT
    In Vivo; 2021; 35(6):3431-3439. PubMed ID: 34697179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discordant prostate specific antigen test results despite WHO assay standardization.
    Boegemann M; Arsov C; Hadaschik B; Herkommer K; Imkamp F; Nofer JR; Gerß J; Albers P; Semjonow A
    Int J Biol Markers; 2018 Aug; 33(3):275-282. PubMed ID: 29734838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update.
    Stephan C; Klaas M; Müller C; Schnorr D; Loening SA; Jung K
    Clin Chem; 2006 Jan; 52(1):59-64. PubMed ID: 16391327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging.
    Catalona WJ; Southwick PC; Slawin KM; Partin AW; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Loveland KG; Bray KR
    Urology; 2000 Aug; 56(2):255-60. PubMed ID: 10925089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
    Khan MA; Partin AW; Rittenhouse HG; Mikolajczyk SD; Sokoll LJ; Chan DW; Veltri RW
    J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermethod differences in results for total PSA, free PSA, and percentage of free PSA.
    Slev PR; La'ulu SL; Roberts WL
    Am J Clin Pathol; 2008 Jun; 129(6):952-8. PubMed ID: 18480013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variability of assay methods for total and free PSA after WHO standardization.
    Foj L; Filella X; Alcover J; Augé JM; Escudero JM; Molina R
    Tumour Biol; 2014 Mar; 35(3):1867-73. PubMed ID: 24092573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation.
    Kort SA; Martens F; Vanpoucke H; van Duijnhoven HL; Blankenstein MA
    Clin Chem; 2006 Aug; 52(8):1568-74. PubMed ID: 16762996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.
    Douglas TH; Morgan TO; McLeod DG; Moul JW; Murphy GP; Barren R; Sesterhenn IA; Mostofi FK
    Cancer; 1997 Jul; 80(1):107-14. PubMed ID: 9210715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PSA Isoforms' Velocities for Early Diagnosis of Prostate Cancer.
    Heidegger I; Klocker H; Pichler R; Horninger W; Bektic J
    Anticancer Res; 2015 Jun; 35(6):3567-70. PubMed ID: 26026127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer.
    Stephan C; Vincendeau S; Houlgatte A; Cammann H; Jung K; Semjonow A
    Clin Chem; 2013 Jan; 59(1):306-14. PubMed ID: 23213080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
    Haese A; Graefen M; Steuber T; Becker C; Pettersson K; Piironen T; Noldus J; Huland H; Lilja H
    Prostate; 2001 Oct; 49(2):101-9. PubMed ID: 11582588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of free-to-total prostate specific antigen variability on the early diagnosis of prostate cancer: a comparative study of three immunoassays.
    de la Taille A; Houlgatte A; Houdelette P; Goluboff ET; Berlizot P; Ricordel I
    Br J Urol; 1998 Sep; 82(3):389-92. PubMed ID: 9772876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total PSA assays.
    Vessella RL; Lange PH; Partin AW; Chan DW; Sokoll LJ; Sasse EA; Crawford ED
    Urology; 2000 Jun; 55(6):909-14. PubMed ID: 10840107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.